Russian Federation
The condition of the liver in patients with stage 5 chronic kidney disease (CKD), especially those on hemodialysis, is a signi†cant medical problem. Impaired kidney function leads to increased stress on the liver, which can cause liver damage. The article discusses the main liver pathologies, such as fatty degeneration, †brosis, and cirrhosis, and connection with CKD and hemodialysis. The article reviews scienti†c literature on liver pathologies in patients with CKD. Data from clinical studies, meta-analyses, and experimental work were used to examine the mechanisms of the toxic e—ects of dialysis solution components on the liver. Studies have shown that patients with stage 5 CKD on hemodialysis often develop fatty liver disease, †brosis, and cirrhosis. The main causes are metabolic disorders, toxin accumulation, and the toxic e—ects of dialysis solution components. It has also been found that hemodialysis can lead to vitamin and mineral de†ciencies, which worsen liver condition. The relationship between liver and kidney function requires a comprehensive approach to treatment. It is important to promptly detect changes in liver condition and adjust therapy to prevent disease progression. Special attention should be paid to managing risk factors such as hyperglycemia, arterial hypertension, and dyslipidemia. The condition of the liver in patients with stage 5 CKD requires special attention. A comprehensive treatment approach, including monitoring liver and kidney function, can signi†cantly improve patients’ quality of life and prevent the development of severe complications. The literature was reviewed for the period from 2017 to 2024 using the websites Pubmed, Springer, eLibrary both Russian and English.
Protein and energy deficiency, fatty liver disease, hemodialysis, liver disorders, kidney damage.
1. Batyushin M. M. Hronicheskaya bolezn' pochek: sovremennoe sostoyanie problemy. Racional'naya farmakoterapiya v kardiologii. 2020;16(6): 938-947. doihttps://doi.org/10.20996/1819-64462020-11-06.
2. Hubutiya M. Sh., Lysenko Yu. S., Mikita Yu. S., Pinchuk A. V. Social'naya znachimost' bolezni i komplaentnost' u pacientov s hropochechnoy nedostatochnost'yu. Uchenye zapiski universiteta im. P. F. Lesgafta.
3. Strokov A. T., Gurevich K. Ya., Il'in A. P., Denisov A. Yu., Zemchenkov A. Yu., Andrusev A. M., Shutov E. V., Kotenko O. H., Zlokazov V. B. Lechenie pacientov s hronicheskoy bolezn'yu pochek 5 stadii (HBP 5) metodami
4. Turebekov 3. T. Orazbaev G. A., Zharmuhanbet L. S. Elektrolitnye narusheniya ne kompensiruemaya gipokaliyemiya na programmnom gemodialize Journal of Clinical Medicine of Kazakhstan. 2018;25(48):40-40.36.
5. Ustimova B. N. Narushenie gemostaza u pacientov, stradayuschih terminal'noy pochechnoy nedostatochnost'yu. Krymskiy terapevticheskiy zhurnal. 2018;(2):63-66.
6. Brus T. V., Pyurveev S. S., Vasil'eva A. V., Zabezhinskiy M. M., Kravcova A. A., Pahomova M. A., Utehin V. I. Morfologicheskie izmeneniya pecheni pri zhirovoy distrofii razlichnoy etiologii. Rossiyskie
7. Stacenko M. E., Turkina S. V., Ermolenko A. A., Gorbacheva E. E., Sabanov A. V. Nealkogol'naya zhirovaya bolezn' pecheni - novyy faktor riska razvitiya hronicheskoy bolezni pochek. Vestnik Volgogradskogo
8. Isaacs S. Nonalcoholic Fatty Liver Disease. Endocrinol Metab Clin North Am. 2023;52(1):149164. doihttps://doi.org/10.1016/j.ecl.2022.06.007.
9. Muydinzhonov P. B., Zhaboraliev A. M., Ahmadalieva U. K., Usmanova U. I. Fibroz pecheni: sovremennye principy diagnostiki. Ekonomika i socium. 2019;12(67):710-714.
10. Parola M., Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. doihttps://doi.org/10.1016/j.mam.2018.09.002.
11. Akalaev R. N., Ariphodzhaeva G. 3., Rashidova C. A., Abdullaev A. N., Hashimov H. A. Kliniko-epidemiologicheskie i patogeneticheskie osobennosti virusnogo gepatita S v otdeleniyah gemodializa.
12. Akalaev R. N., Ariphodzhaeva F. A., Rashidova S. A., Abdullaev A. N., Rahimova N. S., Ariphodzhaeva G. Z., Sharipova V. H., Stopnickiy A. A. Effektivnost' primeneniya protivovirusnyh preparatov pryamogo
13. Zhmurov D. B., Parfenteva M. A., Semenova Yu. B., Rubcov D. A. Cirroz pecheni. Colloquiumjournal. 2020;11(63):57-62. doi:24411/2520-69902020-11732.
14. Bagriy A. E., Homenko M. B., Shverova O. I. Diabeticheskaya nefropatiya: VOCROSY Epidemiologii, terminologii, patogeneza, klinicheskoy mediciny i lechebnoy taktiki (obzor literatury). Krymskiy
15. Borisov A. G., Chernavskiy C. B., Smirnova M. A., Stremouhov A. A. Diabeticheskaya nefropatiya: sovremennye principy klassifikacii, diagnostiki i osobennosti saharosnizhayuschey terapii. Lechaschiy vrach.
16. Grigor'ev K. I., Borzakova C. H., Solov'eva A. L. Dismetabolicheskie nefropatii. Medicinskaya sestra. 2017;(7):18-23. doihttps://doi.org/10.31146/16828658-ecg-183-11-20-24.
17. Terehova O. I., Furtikova A. B. Obschie principy reabilitacii pacientov s saharnym diabetom 1 tipa i diabeticheskoy nefropatiey. Byulleten' nauki i praktiki. 2021;7(12):97-103. doihttps://doi.org/10.33619/2414-2948.
18. Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Biomed Res Int. 2021;2021:1497449. Published 2021 Jul 8. doihttps://doi.org/10.1155/2021/1497449.
19. Latifova N. F. Rol' nekotoryh citokinov pri diabeticheskoy nefropatii. Baykal'skiy medicinskiy zhurnal. 2019;159(4):35-38. doihttps://doi.org/10.34673/2019.39.61.008.
20. Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature. Diab Vasc Dis Res. 2021;18(6):14791641211058856. doihttps://doi.org/10.1177/14791641211058856.
21. Chartakova H. H., Chartakov A. K., Chartakov D. K. Osobennosti profilaktiki nefropatii u bol'nyh saharnym diabetom 2-go tipa. Mirovaya nauka. 2023;11(80):93-95.
22. Mitrofanova A., Merscher S., Fornoni A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. Nat Rev Nephrol. 2023;19(10):629-645. doihttps://doi.org/10.1038/s41581023-00741-w.
23. Vafoeva N. A., Atahanova H. C. Izmenenie central'noy gemodinamiki pri boleznyah pochek. Ekonomika i socium. 2021;10(89):570-575.
24. Zhaybergenova Zh. B., Abdirashitova G. S., Ametova A. C. Hronicheskaya pochechnaya nedostatochnost' kak oslozhnenie gipertonicheskoy bolezni. Ekonomika i socium. 2021;1-1(80):570-579.
25. Osipova E. V., Osipova E. A., Mel'nikova L. V. Znachenie sovremennyh metodov diagnostiki v rannem vyyavlenii gipertonicheskoy nefropatii. Kardiovaskulyarnaya terapiya i profilaktika. 2022;21(1):87-92.
26. Solov'eva A. E., Bayarsayhan M., Villeval'de C. B., Kobalava K. A. Markery povrezhdeniya pecheni pri dekompensacii serdechnoy nedostatochnosti. Eksperimental'naya i klinicheskaya gastroenterologiya
27. Oschepkova O. B., Arhipov E. V., Muhametgalieva G. M., Mihoparova O. Yu. Arterial'naya gipertenziya, ishemicheskaya bolezn' serdca i funkciya pochek pri dlitel'nom nablyudenii. Vestnik sovremennoy
28. Silveira Rossi J. L, Barbalho S. M, Reverete de Araujo R., Bechara M. D, Sloan K. P, Sloan L. A. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev.
29. Nagimullin P. P, Shipulin F. A., Bayalieva A. Zh. Gepatorenal'nyy sindrom v komplekse ostroy pechenochno-pochechnoy nedostatochnosti: sovremennye aspekty kliniki i intensivnoy terapii. Kreativnaya hirurgiya
30. Hadzegova A. B. Funkciya pochek pri serdechnoy nedostatochnosti - prediktor vybora blokatorov paac. Rmzh. Medicinskoe obozrenie. 2023;7(1):30-35.38. doi:https://doi.org/10.32364/2587-6821-20237-1-30-35.
31. Mel'dehanov T. T., Kuttybaev A. D., Imanbekova Zh. A., Terlikbaeva G. A. Toksicheskie lekarstvennye porazheniya pecheni. Vestnik Kazahskogo Nacional'nogo medicinskogo universiteta. 2019;(1):63-66.
32. Sales GTM, Foresto RD. Drug-induced nephrotoxicity. Rev Assoc Med Bras (1992). 2020;66Suppl 1(Suppl 1):s82-s90. Published 2020 Jan 13. doihttps://doi.org/10.1590/1806-9282.66.S1.82.
33. Wu H., Huang J. Drug-Induced Nephrotoxicity: Pathogenic Mechanisms, Biomarkers and Prevention Strategies. Curr Drug Metab. 2018;19(7):559-567. doihttps://doi.org/10.2174/13892002186661 71108154419.
34. Isroilov N. K., Huzhamberdiev U. E. Diagnostika i lechenie hronicheskogo glomerulonefrita. Ekonomika i socium. 2023;1-2(104):278-281.
35. Mel'nik A. A. Metabolicheskiy sindrom i risk hronicheskoy bolezni pochek. Pochki. 2017;6(2):80-90. doihttps://doi.org/10.22141/23071257.6.2.2017.102785.
36. Murkamilov I. T., Sabirov I. S., Fomin B. B., Murkamilova Zh. A., Aydarov Z. A. Sovremennyy vzglyad na problemu lecheniya glomerulonefritov. Mediko-farmacevticheskiy zhurnal «Pul's». 2017;19(12):25-36.
37. Keskinyan V. S., Lattanza B., Reid-Adam J. Glomerulonephritis. Pediatr Rev. 2023;44(9):498512. doihttps://doi.org/10.1542/pir.2021-005259.
38. Sostoyanie bol'nyh s hronicheskoy pochechnoy nedostatochnost'yu, poluchayuschih gemodializ s oslozhneniem gipotonii. Vestnik Oshskogo gosudarstvennogo universiteta. 2022;(4):49-55.
39. Brus T. V., Pyurveev S. S., Vasil'eva A. V., Zabezhinskiy M. M., Kravcova A. A., Pahomova M. A., Utehin V. I. Morfologicheskie izmeneniya pecheni pri zhirovoy distrofii razlichnoy etiologii. Rossiyskie
40. Maurice J., Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018;18(3):245-250. doihttps://doi.org/10.7861/clinmedicine.18-3-245.
41. Pirklbauer M. Hemodialysis treatment in patients with severe electrolyte disorders: Management of hyperkalemia and hyponatremia. Hemodial Int. 2020;24(3):282-289. doi:10.1111/ hdi.12845.
42. Rezende LR, Souza PB, Pereira GRM, Lugon JR. Metabolic acidosis in hemodialysis patients: a review. J Bras Nefrol. 2017;39(3):305311. doihttps://doi.org/10.5935/0101-2800.20170053.
43. Zueva T. B., Urazlina C. E., Zhdanova T. B. Belkovo-energeticheskaya nedostatochnost' pri hronicheskoy bolezni pochek. Vrach. 2021;32(1):2936. dolhttps://doi.org/10.29296/25877305-2021-01-06.
44. Yakovenko A. A., Rumyancev A. Sh. Belkovo energeticheskaya nedostatochnost' u pacientov, poluchayuschih lechenie programmnym gemodializom. Terapevticheskiy arhiv. 2019;91(6):80-86.
45. Zaharchenko A. E., Lazovskaya V. V., Poddubnaya P. V. Vitaminy i ih rol' v obmene veschestv. E-Scio. 2021;2(53):621-631.
46. Tat'yana E., Anastasiya M. Vitamin D — opisanie, pol'za i gde soderzhitsya. Zhurnal zdorovogo pitaniya i dietologii. 2018;3(5):52-67.
47. Hu L., Napoletano A., Provenzano M., et al. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. Int J Mol Sci. 2022;23(20):12223. Published 2022 Oct 13. doihttps://doi.org/10.3390/ijms232012223.
48. Mudunuru S. A, Navarrete J., O’Neill WC. Metabolic alkalosis in hemodialysis patients. Semin Dial. 2023;36(1):24-28. doihttps://doi.org/10.1111/sdi.13068.
49. Tat'yana E. Zhelezo (Fe) dlya organizma — 30 luchshih istochnikov i znachenie dlya zdorov'ya. Zhurnal zdorovogo pitaniya i dietologii. 2021;4(18):66-75.
50. Tat'yana E., Anastasiya M. Kaliy (K, potassium) — opisanie, vliyanie na organizm, luchshie istochniki. Zhurnal zdorovogo pitaniya i dietologii. 2020;3(13):59-70.
51. Osipova O. A., Gosteva E. B., Zhernakova N. I., Belousova O. H., Tatarinceva Yu. V., Hachaturov A. H. Izuchenie vliyaniya urovnya vitamina D na gormonal'no-metabolicheskiy status u bol'nyh s metabolicheskim
52. Taran E. I. Virusnyy gepatit s u pacientov s hronicheskoy bolezn'yu pochek i na zamestitel'noy pochechnoy terapii: diagnostika i lechenie. Pochki. 2020;9(1):80-84. doihttps://doi.org/10.22141/23071257.9.1.2020.197137.
53. Winston A., Wurcel A.G., Gordon C., Goyal N. Viral hepatitis in patients on hemodialysis. Semin Dial. 2020;33(3):254-262. doihttps://doi.org/10.1111/sdi.12882.
54. Kvashnina D. V., Kovalishena O. B., Saperkin N. V. Faktory riska razvitiya geppatita B u pacientov na gemodialize po dannym sistematicheskogo obzora. Fundamental'naya i klinicheskaya medicina.
55. Musabaev B. C. Neobhodimost' sovershenstvovaniya diagnostiki virusnogo gepatita s u bol'nyh s hronicheskoy bolezn'yu pochek, poluchayuschih gemodializ. Nauka i zdravoohranenie.2020;(6):54-62.
